SCHEMBL6312461

SCHEMBL6312461

Cc1nc(C=Cc2ccccc2)cs1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 3/20 0.69
KDM4E B2RXH2 6/20 0.55
ALDH1A1 P00352 5/20 0.55
HPGD P15428 3/20 0.55
GRM4 Q14833 8/20 0.53
RAB9A P51151 4/20 0.53
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
NPC1 O15118 2/20 0.53
PKM P14618 2/20 0.53
HDAC6 Q9UBN7 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
NPSR1 Q6W5P4 1/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2D6 P10635 1/20 0.53
CYP2C9 P11712 1/20 0.53
TSHR P16473 1/20 0.53
NFKB1 P19838 1/20 0.53
CYP2C19 P33261 1/20 0.53
THPO P40225 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6312457 1.00 GRM5 (0.69) GRM5KDM4EALDH1A1HPGDGRM4
SCHEMBL12919337 0.82 GRM5 (0.56) GRM5KDM4EALDH1A1HPGDRAB9A
SCHEMBL5655300 0.82 GRM5 (0.56) GRM5KDM4EALDH1A1HPGDGRM4
SCHEMBL4148438 0.82 GRM5 (1.00) GRM5KDM4EALDH1A1GRM4RAB9A
SCHEMBL4148449 0.82 GRM5 (1.00) GRM5KDM4EALDH1A1GRM4RAB9A
SCHEMBL7239055 0.78 GRM4 (0.53) GRM5KDM4EALDH1A1HPGDGRM4
SCHEMBL7239050 0.78 GRM4 (0.53) GRM5KDM4EALDH1A1HPGDGRM4
SCHEMBL8803696 0.78 MEN1 (0.48) GRM5KDM4EALDH1A1HPGDGRM4
SCHEMBL8803702 0.78 MEN1 (0.48) GRM5KDM4EALDH1A1HPGDGRM4
SCHEMBL3446831 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1599204-A2 SELECTIVE MGLU5 ANTAGONISTS FOR TREATMENT OF NEUROMUSCULAR DYSFUNCTION OF THE LOWER URINARY TRACT Recordati Ireland Limited (IE) 2005-11-30 EP disclosed
US-6956049-B1 Methods of modulating processes mediated by excitatory amino acid receptors MERCK & CO., INC. (US) 2005-10-18 US disclosed
US-20040215284-A1 Treatment of neuromuscular dysfunction of the lower urinary tract with selective mGlu5 antagonists RECORDATI S.A. 2004-10-28 US disclosed
WO-2004067002-A2 SELECTIVE mGlu5 ANTAGONISTS FOR TREATMENT OF NEUROMUSCULAR DYSFUNCTION OF THE LOWER URINARY TRACT RECORDATI IRELAND LIMITED (IE) 2004-08-12 WO disclosed
EP-1214303-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF Merck & Co., Inc. (US) 2002-06-19 EP disclosed
WO-2001016121-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF MERCK & CO., INC. (US) 2001-03-08 WO disclosed